Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.43 |
| ▸ | DPP4 | P27487 | 4/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 8/20 | 0.39 |
| ▸ | CTSS | P25774 | 4/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16258141 | 0.88 | CTSK (0.49) | AAK1DPP4ATMCTSKCTSS | |
| SCHEMBL27800588 | 0.86 | DPP4 (0.47) | AAK1DPP4ATMCTSKCTSS | |
| SCHEMBL14550113 | 0.86 | DPP4 (0.47) | AAK1DPP4ATMCTSKCTSS | |
| SCHEMBL27800590 | 0.86 | DPP4 (0.47) | AAK1DPP4ATMCTSKCTSS | |
| SCHEMBL4664825 | 0.84 | CTSS (0.56) | AAK1ATMCTSKCTSSPTPN1 | |
| SCHEMBL4664829 | 0.84 | CTSS (0.56) | AAK1ATMCTSKCTSSPTPN1 | |
| SCHEMBL19500634 | 0.84 | DPP4 (0.43) | AAK1DPP4ATMCTSKCTSS | |
| SCHEMBL342707 | 0.84 | DPP4 (0.43) | AAK1DPP4ATMCTSKCTSS | |
| SCHEMBL344600 | 0.84 | DPP4 (0.43) | AAK1DPP4ATMCTSKCTSS | |
| SCHEMBL342708 | 0.84 | DPP4 (0.43) | AAK1DPP4ATMCTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | ZIMMERMANN KASPAR | 2010-03-25 | — | — | US | disclosed |
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | ZIMMERMANN KASPAR | 2010-03-25 | — | — | US | disclosed |
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | ZIMMERMANN KASPAR | 2010-03-25 | — | — | US | disclosed |
| EP-2125725-A1 | COMPOUNDS OF FORMULA (I) AS SERINE PROTEASE INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008101953-A1 | COMPOUNDS OF FORMULA (I) AS SERINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101953-A1 | COMPOUNDS OF FORMULA (I) AS SERINE PROTEASE INHIBITORS | NOVARTIS AG (CH) | 2008-08-28 | — | — | WO | disclosed |
| EP-1961742-A1 | compounds of formula (I) as serine protease inhibitors | Novartis AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| WO-2005120494-A1 | 1-`(3R)-AMINO-4-(2-FLUORO-PHENYL)-BUTYL !-PYRROLIDINE-(2R)-CARBOXILIC ACID-BENZYL AMINE DERIVATIVES AND RELATED COMPOUNDS AS DIPEPTIDYL-PEPTIDASE IV (DPP-IV) INHIBITORS FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100076024-A1 | Novel Compounds as Serine Protease Inhibitors | PRSS1, SERPINB1, SPINT2 | AAK1 3047/4885DPP4 97/4885ATM 1978/4885 |
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | AAK1 2780/4885DPP4 1/4885ATM 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.